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Abstract
The incidence of respiratory syncytial virus (RSV) and inﬂuenza
virus infection was determined during three RSV seasons in 158
adult patients consecutively admitted to the intensive care unit with
community-acquired respiratory failure. Nasopharyngeal swabs
were tested for the presence of RSV and inﬂuenza virus by real-time
polymerase chain reaction. Six patients (4%) were positive for RSV
and all recovered. This ﬁnding was in sharp contrast to inﬂuenza (23
(15%) patients, 4 (17%) deaths). In conclusion, even in the midst of
the RSV season, RSV is an infrequent cause of respiratory failure in
adults admitted to the intensive care unit.
Keywords: Adult, inﬂuenza, intensive care unit, respiratory
failure, respiratory syncytial virus
Original Submission: 23 September 2013; Revised
Submission: 3 December 2013; Accepted: 12 December 2013
Editor: L. Kaiser
Article published online: 17 January 2014
Clin Microbiol Infect 2014; 20: O505–O507
10.1111/1469-0691.12503
Corresponding author: L. J. Bont, Heidelberglaan 100, 3584 CX
Utrecht, Postbus 85090, 3508 AB Utrecht, the Netherlands
E-mail: l.bont@umcutrecht.nl
Introduction
Respiratory syncytial virus (RSV) is the most important cause
of bronchiolitis and pneumonia in young children worldwide
[1]. Disease severity depends on the patients’ age and health
status, whereby premature infants are typically at greatest risk.
However, RSV is not exclusively a pathogen in the paediatric
population. Reported incidence rates in the United Kingdom
for adult patients presenting with inﬂuenza-like illness to
general practice have been as high as 20% [2]. RSV illness in
adults is often mild, but can cause signiﬁcant morbidity in the
elderly and in high-risk adults, with mortality rates around 8%
[3–6]. In a population-based cohort study in the United States
RSV infection, independent of bacterial co-infection, was
associated with poor outcome [7]. In a Dutch study, seasonal
mortality in the elderly was attributable to multiple viruses,
including RSV [8]. It has been suggested that RSV infection is a
trigger for acute exacerbation of chronic obstructive pulmo-
nary disease (COPD) [9], and thus may play an important, yet
unrecognized, role in the aetiology and outcome of patients
admitted to the intensive care unit (ICU) with respiratory
failure. In contrast to the paediatric age group, routine testing
for viral infections, including RSV, is not frequently performed
in adult patients.
In this multi-centre observational study incidences of RSV
and inﬂuenza infections were determined in patients over
18 years of age admitted to the ICU with community-acquired
respiratory failure. Participating centres in the Netherlands
were the mixed ICUs at the University Medical Center
Utrecht and the Medical Center Leeuwarden. All consecutive
patients were prospectively included by trained research
physicians in Utrecht and critical care physicians in Leeuwar-
den during the three winter seasons of 2010 until 2013.
Community-acquired respiratory failure was deﬁned by symp-
toms of dyspnoea, cough and/or wheezing present before or
within 48 h after hospital admission and the presence of
respiratory failure requiring ICU admission. The Ethics Com-
mittee at the Medical Center Leeuwarden approved the study
as part of a prospective cohort study. The Ethics Committee at
the University Medical Center Utrecht approved this study and
waived the need for informed consent.
Brushed nasopharyngeal swabs (Copan) were taken upon
ICU admission, stored in viral transportation medium, and
transported to the diagnostic virology laboratory. Real-time
polymerase chain reaction (PCR) was performed for the
detection of RSV and inﬂuenza virus by the MagNA Pure LC
extraction system (Roche Diagnostics, Mannheim, Germany)
and the Taqman 7500 ampliﬁcation platform (Applied Bio-
systems, Foster City, CA, USA) [10]. All data were analysed
with SAS 9.2 (Cary, NC, USA).
A total of 158 patients were included. Data from the
National Institute for Public Health and the Environment
(RIVM) in the Netherlands conﬁrmed that the study periods
concurred with the RSV seasons (Fig. 1). In the majority of
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cases, diagnosis of community-acquired pneumonia was con-
ﬁrmed (Table 1). There were no differences in baseline
characteristics between patients with inﬂuenza and those with
RSV infection. Six patients (4%; 95% CI, 2–8) tested positive
for RSV; all required mechanical ventilation within the ﬁrst
24 h after ICU admission and did not receive antiviral therapy
before or during ICU admission. The median duration of ICU
admission was 7 (IQR 6–18) days. One of the RSV infected
patients was an immunocompetent 61-year-old female with
severe COPD disease. Two other patients with RSV infection
developed acute kidney injury, one of whom required renal
replacement therapy. The remaining three patients had a
relatively uncomplicated course of disease. Sputum and blood
cultures failed to identify bacterial or viral co-pathogens in the
RSV-positive patients. Twenty-three patients (15%; 95% CI,
10–21) had inﬂuenza, of whom four (17%) died. The median
duration of ICU admission was 7 (IQR 2–10) days in patients
with inﬂuenza infection.
This is the largest prospective study deﬁning the incidence
of RSV in adult patients with community-acquired respiratory
failure admitted to either an academic or non-academic ICU,
including patients with or without chronic conditions. The
incidence of RSV infection was 4% and lower than the
observed 15% for inﬂuenza. Only three previous studies have
evaluated RSV infection in ICU patients. One study included a
select group of 122 ICU patients with chronic cardiac or
pulmonary disorders, and found a comparable incidence rate
of 5% [9]. The other study assessed 64 ICU patients with
severe community-acquired and 134 ICU patients with
healthcare-associated pneumonia, and found RSV incidence
rates of 11 and 2%, respectively [11]. The higher incidence
found in the community-acquired group suggested that RSV
infection is primarily found in patients with commu-
nity-acquired respiratory failure. The most recent study
included 70 non-immunocompromised patients with acute
respiratory failure and found an incidence rate of 6% [12].
Based on the limited amount of published data, publication bias
cannot be ruled out, perhaps resulting in an overestimation of
the incidence of RSV in adult ICU patients.
Recently, Lee et al. [4] showed high morbidity and mortality
in adults hospitalized for RSV infections, of whom 10%
required mechanical ventilation. Patients with RSV infection
more frequently had underlying chronic lung diseases and
major systemic co-morbidities compared with patients with
TABLE 1. Patient characteristics
Variable
Respiratory virus
Neither RSV
nor inﬂuenza
(n = 129)
RSV
(n = 6)
Inﬂuenza
(n = 23)
Age (years) 62 (60–68) 60 (50–67) 66 (51–73)
Gender (male) 3 (50) 15 (65) 80 (62)
Apache IV score 68 (52–81) 72 (54–95) 84 (63–105)
Mechanical ventilation within
24 h after ICU admission
6 (100) 14 (65) 100 (78)
Corticosteroid or other
immunosuppressive therapy
3 (50) 3 (13) 26 (20)
Congestive heart failure 0 (0) 0 (0) 13 (10)
COPD 1 (17) 6 (26) 37 (29)
Diagnosis at time of admission
Pneumonia 5 (83) 22 (96) 91 (71)
Congestive heart failure 0 (0) 1 (4) 11 (29)
Other/unknown 1 (17) 0 (0) 25 (20)
ICU length of stay (days) 7 (6–18) 7 (2–10) 6 (3–15)
ICU mortality 0 (0) 4 (17) 19 (15)
Apache, acute physiology and chronic health evaluation; COPD, chronic obstruc-
tive pulmonary disease; ICU, intensive care unit; RSV, respiratory syncytial virus.
Numbers are expressed in median (IQR) and number (%).
FIG. 1. RSV season in the Netherlands and patient inclusion. The lines represent the number of RSV-positive tests per week in the Netherlands
during the 3 years of the study period (left vertical axis) according to The National Institute for Public Health and the Environment (RIVM). The bars
represent the number of patients included each week during this study (right vertical axis).
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inﬂuenza, but both groups had comparable clinical outcomes.
Rapid recognition of RSV as a cause of infection is becoming
more important because of the recent progression in devel-
opment of vaccines and antiviral therapeutics; several agents
have now entered clinical trials. Antisense anti-RSV drugs,
fusion inhibitors and nucleoside analogues show promising
results [13,14]. However, beneﬁcial cost-effectiveness of such
new treatment and prevention modalities will most likely
depend on targeting high-risk populations. Our study demon-
strates that patients admitted to the ICU with commu-
nity-acquired respiratory failure are not part of the high-risk
population. More detailed studies are needed to provide
estimates of the disease prevention and health gains that could
be achieved in more speciﬁc patient populations and settings.
The absence of RSV in the nasopharynx does not exclude
the presence of RSV in the lower respiratory tract. Although
availability of lower respiratory tract specimens might have
increased our diagnostic yield, it has been well established that
the nasopharynx is the porte d’entree for RSV and it is unlikely
that patients with RSV infection were missed in our study [15].
This study did not investigate the presence of other respira-
tory viruses, due to practical reasons and the speciﬁc aim of
comparing RSV with inﬂuenza.
In conclusion, RSV infection is uncommon among adults
with acute community-acquired respiratory failure leading to
ICU admission. Further research is necessary to identify
high-risk adult patients who may possibly beneﬁt from antiviral
therapy and vaccination against RSV in the future.
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